Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer

BACKGROUND: Systemic immune activation, hallmarked by C-reactive protein (CRP) and interleukin-6 (IL-6), can modulate antitumor immune responses. In this study, we evaluated the role of IL-6 and CRP in the stratification of patients with non-small cell lung cancer (NSCLC) treated with immune checkpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Naqash, Abdul Rafeh, McCallen, Justin D, Mi, Emma, Iivanainen, Sanna, Marie, Mona A, Gramenitskaya, Daria, Clark, James, Koivunen, Jussi Pekka, Macherla, Shravanti, Jonnalagadda, Sweta, Polsani, Shanker, Jiwani, Rahim Ali, Hafiz, Maida, Muzaffar, Mahvish, Brunetti, Leonardo, Stroud, Chipman R G, Walker, Paul R, Wang, Kun, Chung, Youngmin, Ruppin, Eytan, Lee, Se-Hoon, Yang, Li V, Pinato, David J, Lee, Joo Sang, Cortellini, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603340/
https://www.ncbi.nlm.nih.gov/pubmed/37852738
http://dx.doi.org/10.1136/jitc-2023-007310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603340/
https://www.ncbi.nlm.nih.gov/pubmed/37852738
http://dx.doi.org/10.1136/jitc-2023-007310

Ejemplares similares